Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Larry Powalisz
- Phone Number: 3217880850
- Email: research@adiamed.com
Study Locations
-
-
Florida
-
Winter Park, Florida, United States, 32789
- Recruiting
- Adia Med Of Winter Park
-
Contact:
- Dr Thomas MD, MD
- Phone Number: 3212312843
- Email: research@adiamed.com
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54311
- Recruiting
- The Lyday Center
-
Contact:
- Rhonda Hilgenberg
- Phone Number: 9203843110
- Email: rhondah@thelydaycenter.com
-
Contact:
- Alina P
- Phone Number: 9203013619
- Email: alinap@thelydaycenter.com
-
Principal Investigator:
- Tami Lyday, DO
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 3-12 years
- Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2)
- Parent/guardian willingness to consider experimental treatments and comply with study requirements
- Ability to attend all scheduled visits
- Able to meet study cost requirements ($12,000 study fee plus bloodwork costs, if applicable) as described in the informed consent
Exclusion Criteria:
- Severe allergies to study products
- Significant uncontrolled medical conditions
- Pregnancy or breastfeeding (if applicable)
- Participation in another interventional trial within 30 days
- Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Glutathione with Stem Cells
|
Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes. Reduced L-glutathione administered Intravenous infusion. |
|
Active Comparator: Glutathione Only
|
Reduced L-glutathione administered Intravenous infusion. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6
Time Frame: Baseline and Month 6
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
Time Frame: Baseline through Month 12
|
Baseline through Month 12
|
|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 3
Time Frame: Baseline and Month 3
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 3
|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 12
Time Frame: Baseline and Month 12
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
- Oxidative stress
- ASD
- Autism
- Autism Spectrum Disorder
- Mesenchymal stem cells
- Glutathione
- Regenerative medicine
- Cellular therapy
- MSCs
- Immune modulation
- Stem cell therapy
- Antioxidant therapy
- Allogeneic stem cells
- Anti-inflammatory therapy
- Intravenous glutathione
- Glutathione therapy
- Autism symptoms
- Hematopoietic stem cells (HSCs)
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Adia Med ASD Research Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.